 HIGH POINT, N.C., Oct. 29, 2020 GLOBE NEWSWIRE -- vTv Therapeutics Inc. Nasdaq: VTVT today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimers Disease CTAD Digital Event on November 4, 2020. The presentation will provide a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimers disease AD in adult patients who also have type 2 diabetes. Patient enrollment in the Elevage Study concluded as of September 2020 and vTv expects to report topline results in December 2020. 